Dr. Michael Williams

Nothing is more rewarding than innovating for animals. ElleVet Sciences was created because we discovered a way to truly elevate the lives of animals and their owners by developing safe, effective hemp CBD + CBDA products. Our team’s combined backgrounds in science, medicine, business, and animal health reflects a dedication to animals through research and innovation. ElleVet is the only CBD + CBDA product proven to work in multiple clinical trials, and is the leader in cannabinoid research and evidence-based products for pets. Currently conducting more than 40 R&D projects / clinical studies at leading universities and referral centers, our team is rapidly growing and expanding our business both domestically and internationally.

While other group practices promote a one size fits all approach, a Pet Partners’ veterinary hospital is encouraged to retain their unique personal style. We work with practices to remove roadblocks and enable them to reach goals they never thought possible. By having us behind-the-scenes to support operations, doctors and their staff are able to dedicate their attention to creating a superior experience for pets and their owners. We find that makes for a pretty satisfying partnership. Pet Partners specializes in purchasing neighborhood animal hospitals. We provide each with a wide suite of business management support services. These services are in place to assist animal hospitals in the pursuit of reaching their goals. Our business was founded by two well-respected veterinarians who practiced for a combined total of almost 40 years and had experienced the opportunities, challenges, inspirations and frustrations that drive a veterinarian and a private practice.

With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Animal & Environmental Health, Healthcare IT, Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

Who are we? Eurolyser Diagnostica has been a global player in the point-of-care testing business for more than 15 years. We are a heavily research driven company and as such have accumulated very specific expertise that allows us to design and manufacture cutting edge technology instruments and test kits. Our products are durable, versatile, maintenance free and – most importantly – every bit as precise as large-scale laboratory devices. We are committed to significantly improve healthcare. Specifically one of its most important aspects: Point-of-care diagnostics. For the benefit of both doctors and patients! What drives us? At Eurolyser, health management and healthcare are our primary concern. We are convinced that medical diagnostics are a key element of modern day healthcare. The faster and more precise a doctor can determine what the patient needs, the faster they can commence treatment. How do we achieve that? We develop and distribute point-of-care instruments and test kits for doctor’s practises or hospital’s ERs. We consider this the next logical step in high-quality healthcare. Our products and services are designed to be beneficial for all relevant parties involved: - It allows physicians to become more independent from laboratories (think waiting periods and paperwork) - Hospitals also strongly benefit from the sped up process - specifically in ERs, where every minute counts - Patients enjoy a significant reduction of necessary visits to hospitals or practices since test results are available within minutes rather than days. - Due to the reductions in redundancies and idle times the healthcare system as a whole will become more efficient and less expensive. For governments and, last but not least, taxpayers. In other words: for every one!

Project Concern International (PCI), a Global Communities Partner, is a global development organization that drives innovation from the ground up to enhance health, end hunger and overcome hardship—resulting in meaningful and measurable change in people’s lives. Guided by the core values of integrity, accountability, respect and creativity, PCI envisions a world in which the most vulnerable people will have the power to lift themselves out of poverty and to create vital, healthy lives for their families and communities now and for the future. Founded in 1961, PCI is an international development and humanitarian assistance organization dedicated to promoting community health and integrated development worldwide. PCI is headquartered in San Diego, CA, and currently operates in 16 countries in Asia, Africa, and the Americas. Sectoral focus areas include humanitarian assistance and disaster risk management; health and nutrition; water and sanitation; food and livelihood security; and disease prevention and mitigation. PCI serves nearly 5 million people annually.

Nothing is more rewarding than innovating for animals. ElleVet Sciences was created because we discovered a way to truly elevate the lives of animals and their owners by developing safe, effective hemp CBD + CBDA products. Our team’s combined backgrounds in science, medicine, business, and animal health reflects a dedication to animals through research and innovation. ElleVet is the only CBD + CBDA product proven to work in multiple clinical trials, and is the leader in cannabinoid research and evidence-based products for pets. Currently conducting more than 40 R&D projects / clinical studies at leading universities and referral centers, our team is rapidly growing and expanding our business both domestically and internationally.